Cough - Pipeline Review, H2 2014

Published: Aug, 2014 | Pages: 63 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Cough - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Cough - Pipeline Review, H2 2014', provides an overview of the Cough's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cough, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cough and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cough
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Cough and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Cough products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cough pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cough
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cough pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Cough Overview 8
Therapeutics Development 9
Pipeline Products for Cough - Overview 9
Pipeline Products for Cough - Comparative Analysis 10
Cough - Therapeutics under Development by Companies 11
Cough - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Cough - Products under Development by Companies 16
Cough - Companies Involved in Therapeutics Development 17
Boehringer Ingelheim GmbH 17
Sanofi 18
Takeda Pharmaceutical Company Limited 19
Daewoong Pharmaceutical Co., Ltd. 20
Ahn-Gook Pharmaceutical Co., Ltd. 21
Hyundai Pharmaceutical Co., Ltd. 22
Hydra Biosciences, Inc. 23
Tris Pharma, Inc. 24
Neos Therapeutics, Inc. 25
AUS Bio Limited 26
Hanmi Pharmaceuticals, Co. Ltd. 27
Cough - Therapeutics Assessment 28
Assessment by Monotherapy Products 28
Assessment by Combination Products 29
Assessment by Target 30
Assessment by Mechanism of Action 32
Assessment by Route of Administration 34
Assessment by Molecule Type 36
Drug Profiles 38
AG-1321001 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
CCP-01 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
tetanus toxoid + reduced diphtheria toxoid + acellular pertussis vaccine adsorbed - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
TAK-361S - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
AG-1321001-SY - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
ambroxol - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
(ambroxol + levodropropizine) - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
HOB-048 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
CCP-07 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
HC-030031 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
AGPPC-709 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
MD-990 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
CCP-06 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
CCP-05 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
CCP-08 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Small Molecule for Cough and Cold - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
DWJ-1340 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Cough - Recent Pipeline Updates 55
Cough - Dormant Projects 56
Cough - Discontinued Products 57
Cough - Product Development Milestones 58
Featured News & Press Releases 58
Jul 22, 2014: Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept 58
Jun 30, 2014: Submission of Tuzistra XR (CCP-01) NDA to FDA 58
Feb 24, 2014: Vernalis Announces Successful Completion of Second Pivotal Bioavailability Study with First Cough Cold Product, CCP-01 58
Dec 11, 2013: Ario Pharma to Develop Novel Therapeutics for Respiratory Indications 59
Jun 28, 2013: TESARO Announces Presentation of Rolapitant Pharmacokinetic Data at the MASCC/ISOO International Symposium 59
Mar 06, 2013: Vernalis's First Product In Cough Cold Pipeline Achieves Proof-of-concept 60
Apr 11, 2012: Cerecor Announces Clearance Of IND For FP01 60
Jan 06, 2012: Tris Pharma Announces US Patent Grant Covering Platform Technology 60
Appendix 62
Methodology 62
Coverage 62
Secondary Research 62
Primary Research 62
Expert Panel Validation 62
Contact Us 63
Disclaimer 63

List of Tables
Number of Products under Development for Cough, H2 2014 9
Number of Products under Development for Cough - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Cough - Pipeline by Boehringer Ingelheim GmbH, H2 2014 17
Cough - Pipeline by Sanofi, H2 2014 18
Cough - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 19
Cough - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2014 20
Cough - Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H2 2014 21
Cough - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2014 22
Cough - Pipeline by Hydra Biosciences, Inc., H2 2014 23
Cough - Pipeline by Tris Pharma, Inc., H2 2014 24
Cough - Pipeline by Neos Therapeutics, Inc., H2 2014 25
Cough - Pipeline by AUS Bio Limited, H2 2014 26
Cough - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2014 27
Assessment by Monotherapy Products, H2 2014 28
Assessment by Combination Products, H2 2014 29
Number of Products by Stage and Target, H2 2014 31
Number of Products by Stage and Mechanism of Action, H2 2014 33
Number of Products by Stage and Route of Administration, H2 2014 35
Number of Products by Stage and Molecule Type, H2 2014 37
Cough Therapeutics - Recent Pipeline Updates, H2 2014 55
Cough - Dormant Projects, H2 2014 56
Cough - Discontinued Products, H2 2014 57